09:20 AM EDT, 03/26/2024 (MT Newswires) -- PharmAla Biotech Holdings Inc. ( MDXXF ) had entered into a binding sales agreement with Numinus Wellness Inc. ( NUMIF ) to provide its GMP LaNeo MDMA for a prospective clinical trial.

PharmAla also announced that key data relating to the in-vivo performance of its ABA family of drug candidates was presented by Dr. Fantegrossi, and colleagues at the 16th annual Behaviour, Biology and Chemistry conference in San Antonio, Texas, from March 22-24. The poster, entitled In Vivo Characterization of MBDB and its Enantiomers in C57 and Autism-like BTBR Mice, presented key findings from the development of PharmAla's proof-of-concept rodent data for its ABA molecule family.